Applicable use standards (AUC) for the usage of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer’s Affiliation and the Society for Nuclear Drugs and Molecular Imaging and revealed on-line Jan. 8 in each Alzheimer’s & Dementia and the Journal of Nuclear Drugs.
Gil D. Rabinovici, M.D., from the College of California San Francisco, and colleagues up to date AUC for amyloid PET and developed AUC for tau PET. Key analysis questions that guided a scientific literature evaluate on medical amyloid/tau PET have been recognized. Based mostly on this evaluate, 17 medical eventualities have been developed wherein amyloid or tau PET could also be thought of.
The researchers discovered that seven eventualities have been rated as applicable, two as unsure, and eight as hardly ever applicable for amyloid PET. 5 eventualities have been rated as applicable, six as unsure, and 6 as hardly ever applicable for tau PET.
Each amyloid and tau PET are thought of applicable for sufferers presenting with gentle cognitive impairment (MCI) or dementia who’re youthful than 65 years and in whom Alzheimer illness (AD) pathology is suspected; for sufferers presenting with MCI or dementia syndrome that could possibly be in step with AD pathology however has atypical options; to tell the prognosis of sufferers presenting with MCI on account of clinically suspected AD pathology; and to find out eligibility for remedy with an permitted amyloid-targeting remedy.
“Amyloid and tau PET can support and enable earlier and more accurate diagnosis, which is essential to high quality care and treatment for dementia, providing appropriate support services and future planning,” Rabinovici stated in a press release.
A number of authors disclosed monetary ties to the pharmaceutical and biotechnology industries.
Extra info:
Gil D. Rabinovici et al, Up to date applicable use standards for amyloid and tau PET: A report from the Alzheimer’s Affiliation and Society for Nuclear Drugs and Molecular Imaging Workgroup, Alzheimer’s & Dementia (2025). DOI: 10.1002/alz.14338
Gil D. Rabinovici et al, Up to date Applicable Use Standards for Amyloid and Tau PET: A Report from the Alzheimer’s Affiliation and Society for Nuclear Drugs and Molecular Imaging Workgroup, Journal of Nuclear Drugs (2025). DOI: 10.2967/jnumed.124.268756
© 2025 HealthDay. All rights reserved.
Quotation:
New standards developed for applicable use of cognitive impairment imaging instruments (2025, January 17)
retrieved 18 January 2025
from https://medicalxpress.com/information/2025-01-criteria-cognitive-impairment-imaging-tools.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
